Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

The increase in weight loss with the higher dose was impressive ... that Zepbound was 47% more effective than the current dose of Wegovy. Shares in Novo Nordisk fell sharply after the announcement.

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.